Clinical trials: Kaposi Sarcoma
Opportunistic Infections, HIV-Related, Cryptococcal Infections
Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi
This study will evaluate the implementation of an enhanced package of care, CD4 and tuberculosis lipoarabinomannan (TB-LAM) tests and the initiation of patients on TB prophylaxis [TPT and CPT], on retention in care and viral…
- Conditions
- Opportunistic Infections, HIV-Related, Cryptococcal Infections, AIDS With Tuberculosis, AIDS-related Kaposi Sarcoma
- Trial name
- NCT05510973
- Testing
- Enhanced package for AHD care
- Where
- 13 sites in Malawi
- Volunteers
- 700 people
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
Acquired Immunodeficiency Syndrome, HIV Infection
Twins Study of Gene Therapy for HIV Infection
This study will test the safety and effectiveness of genetically altered T lymphocytes (white blood cells of the immune system) in reducing viral load in patients infected with the human immunodeficiency virus (HIV).
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infection, Kaposi's Sarcoma
- Trial name
- NCT00001535
- Testing
- Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Sarcoma, Kaposi, HIV Infections
Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients
The purpose of this study is to see if it is safe and effective to use IM862 to treat Kaposi's sarcoma (KS) in AIDS patients.
- Trial name
- NCT00002445
- Testing
- IM862
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 200 people
- Sponsor
- Cytran
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone [R-miniCHOP])…
- Conditions
- Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Trial name
- NCT04799275
- Testing
- Biospecimen Collection, Computed Tomography, Cyclophosphamide
- Where
- 176 sites in United States
- Volunteers
- 422 people
- Sponsor
- National Cancer Institute (NCI)
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Kaposi's Sarcoma
Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions
The purpose of this study is to develop imaging techniques to determine the density of blood vessels and the amount of blood flow in Kaposi s sarcoma (KS) tumors.
- Trial name
- NCT00026793
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03737734
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Alpha Tau Medical LTD.
AIDS-Related Kaposi Sarcoma, Recurrent Kaposi Sarcoma
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
This phase I/II trial studies the side effects and best dose of lenalidomide and to see how well it works in treating patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS).
- Trial name
- NCT01057121
- Testing
- Lenalidomide
- Where
- 13 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03889899
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Alpha Tau Medical LTD.
Sarcoma
Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's…
- Trial name
- NCT00020449
- Testing
- recombinant interleukin-12, paclitaxel, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
AIDS-Related Kaposi Sarcoma, HIV Infection
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
This phase I trial studies the best dose and effects of NT-I7 in treating Kaposi sarcoma in patients with or without HIV. NT-I7 works by using a patient's immune system to fight cancer.
- Conditions
- AIDS-Related Kaposi Sarcoma, HIV Infection, Kaposi Sarcoma
- Trial name
- NCT04893018
- Testing
- Efineptakin alfa
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Fred Hutchinson Cancer Center